Publications by authors named "Nassir Habboubi"
Aims: Meropenem/vaborbactam combination is approved in adults by FDA and EMA for complicated urinary tract infections and by EMA also for other Gram-negative infections. We aimed to characterise the pharmacokinetics of both moieties in an ongoing study in children and use a model-based approach to inform adequate dosing regimens in paediatric patients.
Methods: Over 4196 blood samples of meropenem and vaborbactam (n = 414 subjects) in adults, together with 114 blood samples (n = 39) in paediatric patients aged 3 months to 18 years were available for this analysis.
Article Synopsis
- Elacestrant is a newly approved oral treatment that has shown effectiveness in women with metastatic hormone receptor-positive (HR+) breast cancer, especially those who did not respond to previous therapies.
- A recent study analyzed patients who previously received fulvestrant and found that those treated with elacestrant had better survival rates without disease progression compared to standard endocrine therapy, regardless of mutations in certain genes.
- Elacestrant was also tested in patient-derived models, showing it is effective in cancers resistant to other treatments like fulvestrant, offering a new therapeutic option for patients with HR+/HER2- breast cancer who have relapsed.
Article Synopsis
- JCO Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a severe form of cancer, and a study has evaluated a treatment called tagraxofusp (TAG) in both newly diagnosed and relapsed patients.
- In the study involving 89 patients, TAG led to a 75% overall response rate and a significant number of patients achieving complete response (CR) or clinical CR, with a median follow-up of 34 months.
- TAG was found to be effective for many first-line patients, allowing 51% of those with a positive response to undergo stem-cell transplant, while the treatment had a manageable safety profile with common side effects being mild to moderate.
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.
J Clin Oncol
October 2022
Article Synopsis
- Elacestrant is a new oral medication designed to treat ER-positive/HER2-negative advanced breast cancer, showing promising results in early studies.* -
- In a phase III trial, patients were given either elacestrant or standard endocrine therapy, and results showed that elacestrant significantly prolonged progression-free survival (PFS) in the overall patient group and those with detectable mutations.* -
- While elacestrant was associated with some side effects, such as nausea and a higher rate of treatment discontinuation compared to standard care, it was considered safe and effective for this patient population.*
Neuropathy is a major cause of morbidity and mortality in individuals with diabetes, with no effective therapy to alter the inevitable progression of nerve damage. We hypothesized that mesenchymal stroma cell-like populations, that are characterized as immune modulators also have the potential of inducing angiogenesis and neurite outgrowth, might be useful in treating diabetic peripheral neuropathy (DPN). The aims of this study were to investigate the efficacy and safety of mesenchymal stem cell-like product (PDA-002) in treating DPN.
View Article and Find Full Text PDFUnlabelled: PURPOSE To determine whether irinotecan plus oxaliplatin (IROX) is superior to irinotecan alone in patients with metastatic colorectal cancer (CRC) previously treated with single-agent fluoropyrimidines. PATIENTS AND METHODS A phase III, randomized, open-label, multicenter study of patients with metastatic or recurrent CRC that had progressed or recurred during or after adjuvant or first-line fluoropyrimidines (fluorouracil/leucovorin or capecitabine, the latter only for metastatic CRC). Patients received IROX (irinotecan 200 mg/m(2) plus oxaliplatin 85 mg/m(2)) or irinotecan alone (350 mg/m(2)) every 3 weeks.
View Article and Find Full Text PDF